The Alzheimer’s Drug Discovery Foundation (ADDF) recently reported on the top five Alzheimer’s research advances of 2016. Among these advances was the increasing evidence supporting a key role for neuroinflammation in the progress of Alzheimer’s disease. The article specifically referenced GliaCure’s Phase 1 trial in mild to moderate Alzheimer’s patients using GC021109, which targets inflammation....more »
GliaCure is focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glia targets. GliaCure was founded in 2011 and is based on discoveries by its scientific founder, Philip Haydon, Ph.D., of Tufts University. Professor Haydon has partnered with Michael Szulczewski, who successfully co-founded the imaging company Prairie Technologies, Inc. Their complementary skills in academia and industry provide a solid basis for success in this new venture.
GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery…more »